KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to 22.65%.

  • Regeneron Pharmaceuticals' EBIT Margin fell 34800.0% to 22.65% in Q4 2025 from the same period last year, while for Dec 2025 it was 24.95%, marking a year-over-year decrease of 31500.0%. This contributed to the annual value of 24.95% for FY2025, which is 31500.0% down from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its EBIT Margin stood at 22.65% for Q4 2025, which was down 34800.0% from 27.35% recorded in Q3 2025.
  • Regeneron Pharmaceuticals' EBIT Margin's 5-year high stood at 2517.0% during Q1 2022, with a 5-year trough of 19.54% in Q1 2025.
  • Its 5-year average for EBIT Margin is 214.73%, with a median of 31.94% in 2023.
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 24730000bps in 2022, then tumbled by -24870600bps in 2023.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' EBIT Margin stood at 53.31% in 2021, then surged by 2051bps to 1146.8% in 2022, then tumbled by -98bps to 28.33% in 2023, then dropped by -8bps to 26.13% in 2024, then decreased by -13bps to 22.65% in 2025.
  • Its EBIT Margin stands at 22.65% for Q4 2025, versus 27.35% for Q3 2025 and 29.37% for Q2 2025.